(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
29 September 2005 (29.09.2005)

PCT

(10) International Publication Number
WO 2005/089753 A2

(51) International Patent Classification[7]: A61K 31/423, C07D 413/12, 261/20, A61P 25/18

(21) International Application Number: PCT/EP2005/051105

(22) International Filing Date: 11 March 2005 (11.03.2005)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
04101068.7 16 March 2004 (16.03.2004) EP
60/554,231 18 March 2004 (18.03.2004) US

(71) Applicant *(for all designated States except US)*: **JANSSEN PHARMACEUTICA N.V.** [BE/BE]; Turnhoutseweg 30, B-2340 Beerse (BE).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **KENNIS, Ludo, Edmond, Josephine** [BE/BE]; Janssen Pharmaceutica N.V., Turnhoutseweg 30, B-2340 Beerse (BE). **VANHOOF, Greta, Constantia, Peter** [BE/BE]; Janssen Pharmaceutica N.V., Turnhoutseweg 30, B-2340 Beerse (BE). **BONGARTZ, Jean-Pierre, André, Marc** [BE/BE]; Janssen Pharmaceutica N.V., Turnhoutseweg 30, B-2340 Beerse (BE). **LUYCKX, Marcel, Gerebernus, Maria** [BE/BE]; Janssen Pharmaceutica N.V., Turnhoutseweg 30, B-BEERSE 2340 (BE). **MINKE, Wenda, Eveline** [NL/BE]; Janssen Pharmaceutica N.V., Turnhoutseweg 30, B-2340 Beerse (BE).

(74) Common Representative: **JANSSEN PHARMACEUTICA N.V.**; Turnhoutseweg 30, B-2340 Beerse (BE).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) for the following designations AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, ARIPO patent (BW, GH, GM, KE, LS, MW, MZ,*

[Continued on next page]

(54) Title: BENZISOXAZOLES



(I)

(57) Abstract: The present invention concerns the compounds of formula (I), the *N*-oxide forms, the pharmaceutically acceptable addition salts and the stereochemically isomeric forms thereof, wherein m represents an integer from 1 to 3; X represents amino, hydroxy, -oxo or -Z-R^1; Y is absent when X represents -Z-R^1 and -(C=O)-R^6 when X represents oxo; Z represents carbonyl, -oxy-carbonyl- or -NR^5-carbonyl-; R^1 represents C_{1-4}alkyl, Ar^1, Ar^1-C_{1-4}alkyl-, -NR^3R^4 or -Het^1; R^2 represents hydrogen, halo, nitro, hydroxycarbonyl-, C_{1-4}alkyloxy or C_{1-4}alkyl; R^3 and R^4 are each independently selected from hydrogen, Ar^3 or C_{1-4}alkyl; R^5 represents hydrogen, C_{1-4}alkylcarbonyl- or Ar^4-carbonyl-; R^6 represents a substituent selected from the group consisting of C_{1-4}alkyl, Ar^5, Ar^6-C_{1-4}alkyl- or NR^7R^8; R^7 and R^8 are each independently selected from hydrogen, Het^4 or C_{1-4}alkyl; Het^1 represents a heterocycle selected from oxazolyl, isoxazolyl, imidazolyl or pyrazolyl wherein said heterocycle is optionally substituted with one, two or three substituents selected from the group consisting of amino, C_{1-4}alkyl, hydroxy-C_{1-4}alkyl, phenyl, phenyl-C_{1-4}alkyl- and phenyl substituted with one or more halo substituents; Het^4 represents a heterocycle selected from oxazolyl or isoxazolyl, wherein said heterocycle is optionally substituted with one or more substituents selected from the group consisting of amino, C_{1-4}alkyl, hydroxy-C_{1-4}alkyl-, phenyl, phenyl-C_{1-4}alkyl and phenyl substituted with one or more halo substituents; and Ar^1, Ar^2, Ar^3, Ar^4, Ar^5 or Ar^6 each independently represents phenyl optionally substituted one or where possible two or more substituents selected from halo, nitro, C_{1-4}alkyl, hydroxy or C_{1-4}alkyloxy-.

WO 2005/089753 A2

NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)

— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) for all designations*

— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) for all designations*

— *of inventorship (Rule 4.17(iv)) for US only*

Published:

— *without international search report and to be republished upon receipt of that report*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.